Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Veterans trial aims for Drug-Free remission in blood cancer

NCT ID NCT06520098

Summary

This study is for veterans with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already taking a standard pill (BTKi). It tests if adding a second drug, venetoclax, for one year leads to better results than continuing the standard pill alone. After the year, all drugs are stopped, and doctors monitor if the cancer stays controlled.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Durham VA Medical Center, Durham, NC

    RECRUITING

    Durham, North Carolina, 27705-3875, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Kansas City VA Medical Center, Kansas City, MO

    RECRUITING

    Kansas City, Missouri, 64128-2226, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • San Francisco VA Medical Center, San Francisco, CA

    RECRUITING

    San Francisco, California, 94121-1563, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA

    RECRUITING

    Seattle, Washington, 98108-1532, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.